Chong Kun Dang Pharmaceutical Corp.

Armed with an impressive series A financing that has raked in €77.7m ($84.8m), Augustine Therapeutics has ambitions to be a leading player in the histone deacetylase 6 (HDAC6) inhibition space for the

As South Korea aims to foster the development of global blockbuster drugs and top-tier internationalized biopharma firms in the coming years, amid limited financial and labor resources as well as othe

South Korea’s Ministry of Food and Drug Safety (MFDS) issued approvals for the conduct of 783 clinical trials over the course of 2023, up 10.1% from the previous year, led by an increase in work in on

Drug delivery technologies will continue to be a main theme for the Korean biopharma industry in 2024. Amid a tougher environment to develop innovative therapies, more companies may prioritize develop